Wed, Dec 17, 2014, 7:44 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • vskomarovsky vskomarovsky Jun 13, 2013 1:49 PM Flag

    By Keith Speights for Motley Fool

    The good news is that biotech investors who don't meet the above criteria can often see solid returns. I think Sarepta Therapeutics (NASDAQ: SRPT ) offers a nice opportunity right now.

    First, investors should know what they don't know concerning Sarepta. For example, no one knows for sure yet whether the company's Duchenne musculary dystrophy drug, eteplirsen, will gain accelerated approval by the FDA.

    Second, investors should limit how many shares are bought. Sarepta's stock could take a beating if accelerated approval doesn't happen. There are plenty of other risks that also make it a prudent decision to control the size of any stock purchase.

    Finally, be willing to wait even if accelerated approval isn't granted. Eteplirsen has shown tremendous promise thus far in clinical studies. The long-term prospects for the drug and for Sarepta should be strong.

    Sentiment: Strong Buy

 
SRPT
13.50+0.90(+7.14%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEWed, Dec 17, 2014 4:02 PM EST
Volcano Corporation
NasdaqGSWed, Dec 17, 2014 4:00 PM EST
Auspex Pharmaceuticals, Inc.
NasdaqGMWed, Dec 17, 2014 4:00 PM EST